{
  "id": "63eef7eff36125a42600000e",
  "type": "summary",
  "question": "Which disease is targeted by Fazirsiran?",
  "ideal_answer": "Fazirsiran is an RNA interference therapeutic that was developed for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/35748699"
  ],
  "snippets": [
    {
      "text": "Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "This open-label, phase 2 trial investigated the safety and efficacy of fazirsiran, an RNA interference therapeutic, in patients with liver disease associated with AAT deficiency.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSIONS: In this small trial, fazirsiran was associated with a strong reduction of Z-AAT concentrations in the serum and liver and concurrent improvements in liver enzyme concentrations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/35748699",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}